CAS NO: | 75450-34-9 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | CGP37157 is a potent, selective inhibitor ofNa+/Ca2+exchanger, inhibiting the Na+-induced Ca2+-release from guinea-pig heart mitochondria, with anIC50of 0.8 μM. | ||||||||||||||||
IC50& Target | IC50: 0.8 μM (Na+/Ca2+exchanger)[1] | ||||||||||||||||
体外研究 (In Vitro) | CGP37157 (Compound XVI) is a potent, selective inhibitor of Na+/Ca2+exchanger, inhibiting the Na+-induced Ca2+-release from guinea-pig heart mitochondria, with an IC50of 0.8 μM[1]. CGP37157 (10 μM) shows inhibitory effect on mitochondrial Na+/Ca2+exchanger in cortical neurons, modulates intracellular Ca2+levels via suppresssing voltage-gated calcium channels, and reduces NMDA-induced cytosolic and mitochondrial Ca2+overloads. CGP37157 (10 μM) also reduces NMDA-induced excitotoxicity, and such an effect is via attenuating mitochondrial damage and calpain activity in neurons[2]. CGP37157 (10 μM) in combination with salinomycin significantly attenuates cell viability and increases apoptosis of FaDu and HLaC79 cells. Moreover, CGP37157 has no inhibitory effect on salinomycin tumor toxicity[3]. | ||||||||||||||||
分子量 | 324.22 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C15H11Cl2NOS | ||||||||||||||||
CAS 号 | 75450-34-9 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 125 mg/mL(385.54 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|